MTA1: A Prognosis Indicator of Postoperative Patients with Esophageal Carcinoma

 

 Permissions and Reprints All articles of this category

Abstract

Background To investigate the overexpression of Metastasis-associated gene 1(MTA1) protein and its relationship to the prognosis in esophageal squamous cell cancer after esophagectomy.

Methods 174 patients with middle third squamous cell carcinoma of the esophagus underwent complete resection in Provincial Hospital Affiliated to Shandong University between January 2002 and January 2005. The overexpression of MTA1 protein was detected by immunohistochemistry. Kaplan–Meier method was performed to calculate the survival rate, Cox regression multivariate analysis was performed to determine independent prognostic factors.

Results MTA1 protein overexpression rate in T1, T2, and T3 patients was separately 25.0, 31.9, and 53%, the difference of MTA1 protein overexpression between them was statistically significant (p = 0.017). The overexpression of MTA1 protein in patients with lymph node metastasis was significantly higher than those without metastasis (p = 0.042). MTA1 protein overexpression correlated with significantly worsened 5-year survival for all patients as well as those with T2 and T3 tumors, N0 nodal status or N1 nodal status. However, no significant correlations with T1 patients (p = 0.061). The result of Cox analysis demonstrated that N stage and MTA1 protein overexpression were independent prognostic factors.

Conclusion MTA1 protein overexpression was detected in esophageal squamous cell carcinoma and was found to be significantly associated with the T stage. The patients with MTA1 protein overexpression had a significantly lower 5-year survival rate than without MTA1 protein overexpression. Lymph node metastasis and MTA1 protein overexpression were independent prognostic factors.

• References

• 1 Chen G, Wang Z, Liu XY, Liu FY. Recurrence pattern of squamous cell carcinoma in the middle thoracic esophagus after modified Ivor-Lewis esophagectomy. World J Surg 2007; 31 (5) 1107-1114
  PubMedGoogle Scholar
• 2 Dresner SM, Griffin SM. Pattern of recurrence following radical oesophagectomy with two-field lymphadenectomy. Br J Surg 2000; 87 (10) 1426-1433
  CrossrefPubMedGoogle Scholar
• 3 Zhang MY, Wang Z, Liu XY , et al. The local control of radiotherapy following Ivor-Lewis esophagectomy in the patients with stage IIA middle-third thoracic esophageal cancer. Chinese Journal of Surgery 2008; 46: 1048-1050
  PubMedGoogle Scholar
• 4 Toh Y, Pencil SD, Nicolson GL. Analysis of the complete sequence of the novel metastasis-associated candidate gene, mta1, differentially expressed in mammary adenocarcinoma and breast cancer cell lines. Gene 1995; 159 (1) 97-104
  CrossrefPubMedGoogle Scholar
• 5 Li S-H, Wang Z, Liu X-Y. Metastasis-associated protein 1 (MTA1) overexpression is closely associated with shorter disease-free interval after complete resection of histologically node-negative esophageal cancer. World J Surg 2009; 33 (9) 1876-1881
  CrossrefPubMedGoogle Scholar
• 6 Li SH, Tian H, Yue WM , et al. Overexpression of metastasis-associated protein 1 is significantly correlated with tumor angiogenesis and poor survival in patients with early-stage non-small cell lung cancer. Ann Surg Oncol 2011; 18 (7) 2048-2056
  CrossrefPubMedGoogle Scholar
• 7 Wang Z, Liu XY, Liu FY, Chen JH. [A study of correlation between early postoperative relapse with lymph node micrometastasis in patients with N0 esophageal cancer]. Zhonghua Wai Ke Za Zhi 2004; 42 (2) 68-71
  PubMedGoogle Scholar
• 8 Tachibana M, Kinugasa S, Yoshimura H, Dhar DK, Nagasue N. Extended esophagectomy with 3-field lymph node dissection for esophageal cancer. Arch Surg 2003; 138 (12) 1383-1389 , discussion 1390
  CrossrefPubMedGoogle Scholar
• 9 Shields TW. General Thoracic Surgery. Vol. 2. 5th ed. Philadelphia: Lippincott Williams and Wilkins; 2000: 1905
  Google Scholar
• 10 Law S, Wong J. Two-field dissection is enough for esophageal cancer. Dis Esophagus 2001; 14 (2) 98-103
  CrossrefPubMedGoogle Scholar
• 11 Wang Z, Liu XY, Liu FY , et al. Ivor-Lewis esophagectomy for treatment of esophageal cancer and Cox regression analysis of prognostic factors. Tumor 2004; 24 (3) 286-289
  PubMedGoogle Scholar
• 12 Wang Z, Liu XY, Chen G , et al. The evaluation for therapeutic efficacy of the modified Ivor-Lewis surgery on squamous cell cancer in the middle-third thoracic esophagus. Chinese Journal of Clinical Oncology 2006; 33: 1012-1015
  PubMedGoogle Scholar
• 13 Kumar R, Wang RA, Bagheri-Yarmand R. Emerging roles of MTA family members in human cancers. Semin Oncol 2003; 30 (5, Suppl 16) 30-37
  PubMedGoogle Scholar
• 14 Nicolson GL, Nawa A, Toh Y, Taniguchi S, Nishimori K, Moustafa A. Tumor metastasis-associated human MTA1 gene and its MTA1 protein product: role in epithelial cancer cell invasion, proliferation and nuclear regulation. Clin Exp Metastasis 2003; 20 (1) 19-24
  CrossrefPubMedGoogle Scholar
• 15 Mazumdar A, Wang RA, Mishra SK , et al. Transcriptional repression of oestrogen receptor by metastasis-associated protein 1 corepressor. Nat Cell Biol 2001; 3 (1) 30-37
  CrossrefPubMedGoogle Scholar
• 16 Yan C, Wang H, Toh Y, Boyd DD. Repression of 92-kDa type IV collagenase expression by MTA1 is mediated through direct interactions with the promoter via a mechanism, which is both dependent on and independent of histone deacetylation. J Biol Chem 2003; 278 (4) 2309-2316
  CrossrefPubMedGoogle Scholar
• 17 Hofer MD, Menke A, Genze F, Gierschik P, Giehl K. Expression of MTA1 promotes motility and invasiveness of PANC-1 pancreatic carcinoma cells. Br J Cancer 2004; 90 (2) 455-462
  CrossrefPubMedGoogle Scholar
• 18 Jang KS, Paik SS, Chung H, Oh YH, Kong G. MTA1 overexpression correlates significantly with tumor grade and angiogenesis in human breast cancers. Cancer Sci 2006; 97 (5) 374-379
  CrossrefPubMedGoogle Scholar
• 19 Martin MD, Hilsenbeck SG, Mohsin SK , et al. Breast tumors that overexpress nuclear metastasis-associated 1 (MTA1) protein have high recurrence risks but enhanced responses to systemic therapies. Breast Cancer Res Treat 2006; 95 (1) 7-12
  CrossrefPubMedGoogle Scholar
• 20 Hofer MD, Kuefer R, Varambally S , et al. The role of metastasis-associated protein 1 in prostate cancer progression. Cancer Res 2004; 64 (3) 825-829
  CrossrefPubMedGoogle Scholar
• 21 Balasenthil S, Broaddus RR, Kumar R. Expression of metastasis-associated protein 1 (MTA1) in benign endometrium and endometrial adenocarcinomas. Hum Pathol 2006; 37 (6) 656-661
  CrossrefPubMedGoogle Scholar
• 22 Ryu SH, Chung YH, Lee H , et al. Metastatic tumor antigen 1 is closely associated with frequent postoperative recurrence and poor survival in patients with hepatocellular carcinoma. Hepatology 2008; 47 (3) 929-936
  CrossrefPubMedGoogle Scholar
• 23 Mahoney MG, Simpson A, Jost M , et al. Metastasis-associated protein (MTA)1 enhances migration, invasion, and anchorage-independent survival of immortalized human keratinocytes. Oncogene 2002; 21 (14) 2161-2170
  CrossrefPubMedGoogle Scholar
• 24 Toh Y, Nicolson GL. The role of the MTA family and their encoded proteins in human cancers: molecular functions and clinical implications. Clin Exp Metastasis 2009; 26 (3) 215-227
  CrossrefPubMedGoogle Scholar
• 25 Qian H, Lu N, Xue L , et al. Reduced MTA1 expression by RNAi inhibits in vitro invasion and migration of esophageal squamous cell carcinoma cell line. Clin Exp Metastasis 2005; 22 (8) 653-662
  CrossrefPubMedGoogle Scholar
• 26 Toh Y, Kuwano H, Mori M, Nicolson GL, Sugimachi K. Overexpression of metastasis-associated MTA1 mRNA in invasive oesophageal carcinomas. Br J Cancer 1999; 79 (11-12) 1723-1726
  CrossrefPubMedGoogle Scholar